Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(03): 291-294
DOI: 10.4103/ijmpo.ijmpo_161_20
Editorial Commentary

100-Year-Old Vaccine for a Novel Virus: Killing Two Birds with One Stone!

Chetan Dhamne
Department of Medical Oncology, TMC, Mumbai, Maharashtra, India
,
Gagan Prakash
Department of Surgical Oncology, TMC, Mumbai, Maharashtra, India
,
Gaurav Narula
Department of Medical Oncology, TMC, Mumbai, Maharashtra, India
,
Shripad Banavali
Department of Medical Oncology, TMC, Mumbai, Maharashtra, India
,
Jyoti Bajpai
Department of Medical Oncology, TMC, Mumbai, Maharashtra, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
Also available at
   Permissions and Reprints

Corrected by:

Erratum: 100-Year-Old Vaccine for a Novel Virus: Killing Two Birds with One Stone!Indian J Med Paediatr Oncol 2020; 41(03): 628-628
DOI: 10.4103/0971-5851.293847

Introduction

The coronavirus pandemic has spread like wildfire across the globe. Some countries are more affected than others while children seem to have a milder form of the disease as compared to adults.[1] We are still grappling to understand the reason behind these disparities. There appears to be a correlation between Bacillus Calmette–Guérin (BCG) vaccination and protection against COVID-19.[2],[3] Some experts hypothesize that countries offering BCG vaccine in the national immunization program at birth seem to have a lower death rate from COVID-19.[3] Whether this can be attributed to the BCG vaccine or a less virulent virus strain or social distancing measures or because countries like India are just entering phase III of the epidemic will only be known retrospectively. If BCG is indeed the reason for this protective effect, can it be attributed to persistence of “heterologous” or “off-target” effects of the BCG vaccine, will unfold over the next few months. Banking on the “heterologous effect” of BCG, two clinical trials NCT04327206 and NCT04328441 propose to administer prophylactic BCG vaccine to health-care providers in Australia and the Netherlands respectively. At this point in time, there are 3 trials in the Clinical Trials Registry of India using different BCG strains to harness this heterologous effect against COVID-19. The research hypothesis is activation of the innate immune system to protect against progression of the Coronavirus infection.[4] In this article, we try to understand the underlying mechanisms of immune protection, “trained immunity” conferred by the BCG vaccine and review some epidemiological evidence that support or refute the hypothesis.



Publication History

Received: 15 April 2020

Accepted: 12 May 2020

Article published online:
28 June 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z. et al. Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China. Pediatrics 2020; e20200702
    CrossrefPubMedSearch in Google Scholar
  • 2 Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu G. et al. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: An epidemiological study. medRxiv 2020; 03: 24-20042937
    Search in Google Scholar
  • 3 Hegarty P, Sfakianos J, Giannarini G, DiNardo A, Kamat A. Covid-19 and Bacillus Calmette-Guerin: What is the Link?. Eur Urol Oncol 2020;
    CrossrefPubMedSearch in Google Scholar
  • 4 Available from: https://clinicaltrials.gov/ct2/results?term=BCG& cond=COVID-19. [Last accessed 2020 May 07].
  • 5 Curtis N. BCG vaccination and all-cause neonatal mortality. Pediatr Infect Dis J 2019; 38: 195-7
    CrossrefPubMedSearch in Google Scholar
  • 6 Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: A meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367: 1173-80
    CrossrefPubMedSearch in Google Scholar
  • 7 Zimmermann P, Finn A, Curtis N. Does BCG vaccination protect against nontuberculous mycobacterial infection? A systematic review and meta-analysis. J Infect Dis 2018; 218: 679-87
    CrossrefPubMedSearch in Google Scholar
  • 8 Zimmermann P, Curtis N. The influence of BCG on vaccine responses – A systematic review. Expert Review of vaccines 2018; 17: 547-754
    CrossrefPubMedSearch in Google Scholar
  • 9 Higgins JP, Soares-Weiser K, López-López JA, Kakourou A, Chaplin K, Christensen H. et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: Systematic review. BMJ 2016; 355: i5170
    CrossrefPubMedSearch in Google Scholar
  • 10 Hollm-Delgado MG, Stuart EA, Black RE. Acute lower respiratory infection among Bacille Calmette-Guérin (BCG)-vaccinated children. Pediatrics 2014; 133: e73 -81
    CrossrefPubMedSearch in Google Scholar
  • 11 de Castro MJ, Pardo-Seco J, Martinón-Torres F. Nonspecific (Heterologous) Protection of Neonatal BCG Vaccination Against Hospitalization Due to Respiratory Infection and Sepsis. Clin Infect Dis 2015; 60: 1611-9
    CrossrefPubMedSearch in Google Scholar
  • 12 Netea MG, Quintin J, van der MeerJW. Trained immunity: A memory for innate host defense. Cell Host Microbe 2011; 9: 355-61
    Search in Google Scholar
  • 13 Kleinnijenhuis J, Quintin J, Preijers F, Joosten L, Ifrim D, Saeed S. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. PNAS 2012; 109: 1753742
    CrossrefPubMedSearch in Google Scholar
  • 14 Arts RJ, Carvalho A, La Rocca C, Palma C, Rodrigues F, Silvestre R. et al. Immunometabolic pathways in BCG-induced trained immunity. Cell Rep 2016; 17: 2562-71
    CrossrefPubMedSearch in Google Scholar
  • 15 Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Jacobs C, Xavier RJ. et al. BCG-induced trained immunity in NK cells: Role for non-specific protection to infection. Clin Immunol 2014; 155: 213-9
    CrossrefPubMedSearch in Google Scholar
  • 16 Brandau S, Suttmann H, Riemensberger. Seitzer U, Arnold J, Durek C. et al. Perforinmediated lysis of tumor cells by mycobacterium bovis bacillus calmette guerin activated killer cells. Clin Can Res 2000; 6: 372938
    Search in Google Scholar
  • 17 Leentjens J, Kox M, Stokman R, Gerretsen J, Diavatopoulos DA, van CrevelR. et al. BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study. J Infect Dis 2015; 212: 1930-8
    CrossrefPubMedSearch in Google Scholar
  • 18 Floc'h F, Werner G. Increased resistance to virus infections of mice inoculated with BCG (Bacillus Calmetteguerin). Ann Immunol 1976; 127: 17386
    Search in Google Scholar
  • 19 Aaby P, Benn CS. Saving lives by training innate immunity with bacilli Calmette-Guerin vaccine. Proc Natl Acad Sci U S A 2012; 109: 17317-8
    CrossrefPubMedSearch in Google Scholar
  • 20 Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM. et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: Beneficial nonspecific effects in the neonatal period?. J Infect Dis 2011; 204: 245-52
    CrossrefPubMedSearch in Google Scholar
  • 21 Biering-Sørensen S, Aaby P, Napirna BK, Roth A, Ravn H, Rodrigues H. et al. Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact. Pediatr Infect Dis J 2012; 31: 306-8
    CrossrefPubMedSearch in Google Scholar
  • 22 Schaible UE, Linnemann L, Redinger N, Patin BC, Dallenga T. Strategies to Improve Vaccine Efficacy against Tuberculosis by Targeting Innate Immunity. Front Immunol 2017; 8: 1755
    CrossrefPubMedSearch in Google Scholar
  • 23 Dye C. Making wider use of the world's most widely used vaccinie: Bacille Calmette-Guerin revaccination reconsidered. J Royal Soc Interf 2013; Interface.10: 20130365
    CrossrefPubMedSearch in Google Scholar
  • 24 Dockrell HM, Smith SG. What have we learnt about BCG vaccination in the last 20 years?. Front Immunol 2017; 8: 1134
    CrossrefPubMedSearch in Google Scholar
  • 25 WHO statement on BCG revaccination for the prevention of tuberculosis. Bulletin of the World Health Organization 1995; 73: 805-10
    Search in Google Scholar
  • 26 Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N. et al. Prevention of M. tuberculosis infection with H4:IC3l vaccine or BCG revaccination. N Engl J Med 2018; 379: 138-49
    CrossrefPubMedSearch in Google Scholar
  • 27 de Bree C, van Crevel R, Netea MG. H4:IC31 vaccine or BCG revaccination for tuberculosis. N Engl J Med 2018; 379: 1969
    CrossrefPubMedSearch in Google Scholar
  • 28 Rakshit S, Ahmed A, Adiga V, Sundararaj BK, Sahoo PN, Kenneth J. et al. BCG revaccination boosts adaptive polyfunctional Th1/Th17 and innate effectors in IGRA+and IGRA Indian adults. JCI Insight 2019; 4: e130540
    CrossrefPubMedSearch in Google Scholar